Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer What is this summary about?There are only a few current treatment options for people with newly diagnosed advanced or recurrent endometrial cancer (cancer that has returned).The DUO-E study is testing an immunotherapy, durvalumab, and a targeted therapy, olaparib, in people with newly diagnosed advanced endometrial cancer or recurrent endometrial cancer.Durvalumab blocks the activity of a protein called PD-L1 (programmed death-ligand 1).This makes cancer cells more susceptible to being killed by immune cells.Olaparib inhibits a protein called PARP (poly [ADP-ribose] polymerase), thereby stopping cancer cells from being able to repair their DNA.This can cause cancer cells to die or make them more visible to the immune system.Mismatch repair (MMR) is a DNA repair mechanism, and patients with endometrial cancer can be defined as having tumors that are able to carry out mismatch repair (mismatch repair proficient [pMMR]) or are not able to carry out mismatch repair (mismatch repair deficient [dMMR]).DUO-E enrolled people with either mismatch repair proficient (pMMR) or mismatch repair deficient (dMMR) tumors.DUO-E investigated whether chemotherapy + durvalumab followed by either durvalumab or durvalumab + olaparib can improve outcomes compared with chemotherapy alone. SummaryThis summary is based on the article 'Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial' which can be read for free at: https://ascopubs.org/doi/10.1200/JCO.23.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-04-06
DOI
https://doi.org/10.1080/14796694.2026.2638677
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer

Tadaaki Nishikawa, Birutė Brasiūnienė, Dagmara Klasa-Mazurkiewicz, Joseph de la Garza et al.
Future Oncology
Endometrial and Cervical Cancer Treatments
article

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer

Tadaaki Nishikawa, Birutė Brasiūnienė, Dagmara Klasa-Mazurkiewicz, Joseph de la Garza, Todd Tillmanns, C. Papadimitriou, Kristi McIntyre, Jessica Thomes Pepin, M. Gold, Kathleen N. Moore, F. Contreras Mejia, Michael J. Sundborg, Kathryn P. Pennington, Hye Sook Chon, Conor Donnelly, A. Shai, X. Liu, Jalid Sehouli, Zoltan Novak, Ji-Hong Liu, Jung-Yun Lee, Marta Gil-Martin, Els Van Nieuwenhuysen, Stephanie V. Blank, Andreia Cristina De Melou, Ke Wang, on behalf of the DUO-E Investigators, Michael McCollum, Shannon N. Westin
article en

Abstract

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer What is this summary about?There are only a few current treatment options for people with newly diagnosed advanced or recurrent endometrial cancer (cancer that has returned).The DUO-E study is testing an immunotherapy, durvalumab, and a targeted therapy, olaparib, in people with newly diagnosed advanced endometrial cancer or recurrent endometrial cancer.Durvalumab blocks the activity of a protein called PD-L1 (programmed death-ligand 1).This makes cancer cells more susceptible to being killed by immune cells.Olaparib inhibits a protein called PARP (poly [ADP-ribose] polymerase), thereby stopping cancer cells from being able to repair their DNA.This can cause cancer cells to die or make them more visible to the immune system.Mismatch repair (MMR) is a DNA repair mechanism, and patients with endometrial cancer can be defined as having tumors that are able to carry out mismatch repair (mismatch repair proficient [pMMR]) or are not able to carry out mismatch repair (mismatch repair deficient [dMMR]).DUO-E enrolled people with either mismatch repair proficient (pMMR) or mismatch repair deficient (dMMR) tumors.DUO-E investigated whether chemotherapy + durvalumab followed by either durvalumab or durvalumab + olaparib can improve outcomes compared with chemotherapy alone. SummaryThis summary is based on the article 'Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial' which can be read for free at: https://ascopubs.org/doi/10.1200/JCO.23.

Future OncologyVol. 22(9)
Kurume University (JP), Gynecologic Oncology Group (US), The University of Texas MD Anderson Cancer Center (US), Sun Yat-sen University (CN), University of Tennessee Health Science Center (US), Yonsei University (KR), Texas Health Dallas (US), Rambam Health Care Campus (IL), Tianjin Medical University Cancer Institute and Hospital (CN), University of Oklahoma Medical Center (US), Moffitt Cancer Center (US), Institut d'Investigació Biomédica de Bellvitge (ES), National Cancer Centre Japan (JP), Virginia Oncology Associates (US), National Cancer Center (US), Fred Hutch Cancer Center (US), Urology San Antonio (US), Oklahoma Cancer Specialists and Research Institute (US), West Cancer Center (US), Alaska Women's Cancer Care (US), AstraZeneca (Netherlands) (NL), AstraZeneca (Singapore) (SG), Hellenic Cooperative Oncology Group (GR), Instituto Nacional de Cancerología (CO), FirstHealth of the Carolinas (US), AstraZeneca (Poland) (PL), Instituto Nacional de Câncer - INCA (BR), Duran i Reynals Hospital (ES), National Cancer Center Hospital East (JP), Sun Yat-sen University Cancer Center (CN), AstraZeneca (Spain) (ES), Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (DE), National Cancer Institute (LT), Tokyo National Hospital (JP), Minnesota Oncology (US), Gdańsk Medical University (PL), Icahn School of Medicine at Mount Sinai (US)
AstraZeneca
Openalex Percentile: Top 28%
Endometrial and Cervical Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.